Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of IQVIA Holdings Inc. NYSE: IQV. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
- Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
- Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
- Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
- Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
- Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
IQVIA Stock Up 3.5%
NYSE:IQV traded up $5.02 during trading hours on Wednesday, reaching $147.80. The company's stock had a trading volume of 2,684,601 shares, compared to its average volume of 1,919,131. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The business's 50-day moving average is $149.24 and its 200-day moving average is $179.93. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $25.57 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.54 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Institutional Trading of IQVIA
A number of institutional investors have recently bought and sold shares of IQV. Howard Capital Management Inc. increased its position in shares of IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after acquiring an additional 54 shares in the last quarter. Continuum Advisory LLC raised its holdings in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the last quarter. Ballentine Partners LLC grew its position in IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares in the last quarter. Independent Advisor Alliance boosted its stake in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after buying an additional 72 shares during the last quarter. Finally, Magnolia Capital Advisors LLC increased its position in shares of IQVIA by 2.9% in the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after acquiring an additional 74 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Upgrades and Downgrades
IQV has been the topic of a number of research analyst reports. Truist Financial lowered their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Barclays cut their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. Finally, JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $226.32.
Read Our Latest Stock Report on IQVIA
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About IQVIA
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
